Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)

Karacin, CengizÖksüzoğlu, BernaDemirci, AyşeKeskinkılıç, MerveKöse Baytemur, NaziyetYılmaz, FundaSelvi, OğuzhanHacıbekiroğlu, İlhan2023-03-272023-03-272023Karacin, C., Öksüzoğlu, B., Demirci, A., Keskinkılıç, M., Köse Baytemur, N., Yılmaz, F. ... Hacıbekiroğlu, İ. (2023). Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023). BMC Cancer, 23(1). https://dx.doi.org/10.1186/s12885-023-10662-31471-2407https://dx.doi.org/10.1186/s12885-023-10662-3https://hdl.handle.net/20.500.12511/10700Following publication of the original article [1], the authors reported an error in the author name of Enes Erul.enAttribution 4.0 Internationalinfo:eu-repo/semantics/openAccessCDK 4/6 Inhibitor TherapyBreast CancerDisease ProgressionEfficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (BMC Cancer, (2023), 23, 1, (136), 10.1186/s12885-023-10609-8)Other23110.1186/s12885-023-10662-3Q20009411474000012-s2.0-8514897068336849943Q2